2014 Grants & Awards
Grants-in-aid of research RECIPIENTS
Crohn’s and Colitis Canada's Grants-in-Aid of Research program supports Canadian inflammatory bowel disease (IBD) research. The intention of the program is to help advance prevention, treatments, health policy, and to ultimately move us closer to discovering cures for Crohn's disease and ulcerative colitis. These grants support Canadian research projects which have a defined objective and are conducted by an investigator who is either working alone or in collaboration with others. The grants are awarded for up to three years at a maximum of $125,000 per year.
The selection process for the Grants-in-Aid of Research competition is very competitive as each research proposal submitted by either a Canadian researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel comprised of scientific experts and lay persons. The Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2014 recipients of the Grants-in-Aid of Research.
Dr. Wallace MacNaughton | University of Calgary
Co-investigator: Dr. Paul Beck
How PAR2 regulates death of epithelial cells that line the intestine and turns off inflammation.
Dr. Andre Buret | University of Calgary
Co-investigators: Dr. Hans Vogel, Dr. Joe Harrison, and Dr. Paul Beck
How microbiota biofilms cause post-infectious flare-ups in IBD.
Dr. Simon Hirota | University of Calgary
Co-investigator: Dr. Thomas Chang
How PXR keeps the inner lining of the gut tight and protects against the damaging effects of inflammation.
Dr. Kris Chadee | University of Calgary
How mucin prevents gut microbes and toxins from directly interacting with the underlying gut epithelium.
Dr. Aleixo Muise | The Hospital for Sick Children
Co-investigator: Dr. Daniella Rotin
How certain genes help control the leakiness of the bowel in IBD.
Dr. Mark Lathrop | McGill Universityy
Co-investigator: Dr. Tomi Pastinen
Use high-tech sequencing platform to uncover new types of high-risk genetic risk factors in IBD.
Dr. Brian Coombes | McMaster University
How E. coli infection is linked to post-infectious IBS and IBD.
Dr. Dean Tripp | Queen’s University
Co-investigator: Dr. Mike Beyak
Understanding and improving the psychosocial risk factors of IBD pain and poorer quality of life.
Dr. Eric Benchimol | Children’s Hospital of Eastern Ontario
Co-investigators: Dr. Harminder Singh, Dr. Anthony Otley, Dr. Anne Griffiths, Dr. Geoffrey Nguyen, Dr. Matthew Carroll, and Dr. Alain Bitton
Describe variation of how and when care is being provided in Canadian children with IBD.
INNOVATIONS IN IBD GRANT RECIPIENTS
The Innovations in IBD Grant is a one-year grant, valued at up to $50,000 that funds novel or innovative approaches to IBD research. The grant stimulates and supports research which may not be encompassed within the boundaries of traditional medical research. This award is open to both Canadian and international applicants.
Similar to the Grants-in-Aid of Research, the selection process for the Innovations in IBD Grant competition is very competitive as each research proposal submitted by either a researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel. Comprised of scientific experts and lay persons, the Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2017 recipients of the Innovations in IBD Grant.
Dr. Charles Bernstein | University of Manitoba
Co-investigators: Dr. Laura Targownik, Dr. Hillary Steinhart, and Dr. John Marshall
Denosumab for the treatment of Crohn’s disease.
Dr. Stephen Girardin | University of Toronto
Co-investigator: Dr. David Prescott
Targeted genome editing in human intestinal epithelial cells.
Dr. Andrew Stadnyk | IWK Health Centre
Co-investigator: Dr. Anthony Otley
An innovative approach to cell therapy for Crohn’s disease.
Dr. Stuart Turvey | University of British Columbia
Co-investigators: Dr. Laura Sly, and Dr. Hong Yang
Development of anti-inflammatory nanomedicine for inflammatory bowel disease.